Literature DB >> 24900668

The structure of anthracycline derivatives determines their subcellular localization and cytotoxic activity.

Pazit Shaul1, Michael Frenkel2, Elinor Briner Goldstein1, Leonid Mittelman2, Assaf Grunwald1, Yuval Ebenstein1, Ilan Tsarfaty3, Micha Fridman1.   

Abstract

The cytotoxic activities and subcellular localizations of clinically used and synthetic analogues of the anthracycline family of chemotherapeutic agents were studied. The structures of the anthracycline derivatives affected their cytotoxicity and the time required for these compounds to exert cytotoxic effects on tumor cells. Fluorescent DNA intercalator displacement experiments demonstrated that there was no correlation between the DNA intercalation properties and the cytotoxicity of the studied anthracycline derivatives. Confocal microscopy experiments indicated that structural differences led to differences in subcellular localization. All studied anthracycline derivatives were observed in lysosomes, suggesting that this organelle, which is involved in several processes leading to malignancy, may contain previously unidentified molecular targets for these antitumor agents.

Entities:  

Keywords:  anthracyclines; antitumor agents; cytotoxic activity; subcellular localization

Year:  2013        PMID: 24900668      PMCID: PMC4027571          DOI: 10.1021/ml3002852

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  19 in total

Review 1.  Mitochondria as subcellular targets for clinically useful anthracyclines.

Authors:  K Jung; R Reszka
Journal:  Adv Drug Deliv Rev       Date:  2001-07-02       Impact factor: 15.470

2.  Automatic and quantitative measurement of protein-protein colocalization in live cells.

Authors:  Sylvain V Costes; Dirk Daelemans; Edward H Cho; Zachary Dobbin; George Pavlakis; Stephen Lockett
Journal:  Biophys J       Date:  2004-06       Impact factor: 4.033

3.  Parsing the free energy of anthracycline antibiotic binding to DNA.

Authors:  J B Chaires; S Satyanarayana; D Suh; I Fokt; T Przewloka; W Priebe
Journal:  Biochemistry       Date:  1996-02-20       Impact factor: 3.162

4.  Targeting anthracycline-resistant tumor cells with synthetic aloe-emodin glycosides.

Authors:  Elinor Breiner-Goldstein; Zoharia Evron; Michael Frenkel; Keren Cohen; Keren Nir Meiron; Dan Peer; Yael Roichman; Eliezer Flescher; Micha Fridman
Journal:  ACS Med Chem Lett       Date:  2011-05-12       Impact factor: 4.345

5.  Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.

Authors:  Emanuela Salvatorelli; Simone Guarnieri; Pierantonio Menna; Giovanni Liberi; Antonio M Calafiore; Maria A Mariggiò; Alvaro Mordente; Luca Gianni; Giorgio Minotti
Journal:  J Biol Chem       Date:  2006-01-19       Impact factor: 5.157

6.  A short and efficient transformation of rhamnose into activated daunosamine, acosamine, ristosamine and epi-daunosamine derivatives, and synthesis of an anthracycline antibiotic acosaminyl-epsilon-iso-rhodomycinone.

Authors:  B Renneberg; Y M Li; H Laatsch; H H Fiebig
Journal:  Carbohydr Res       Date:  2000-12-01       Impact factor: 2.104

7.  Cooperative cytotoxicity of methyl jasmonate with anti-cancer drugs and 2-deoxy-D-glucose.

Authors:  Alina Heyfets; Eliezer Flescher
Journal:  Cancer Lett       Date:  2006-11-27       Impact factor: 8.679

8.  Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents.

Authors:  J C Kwok; D R Richardson
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

Review 9.  Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.

Authors:  Giorgio Minotti; Pierantonio Menna; Emanuela Salvatorelli; Gaetano Cairo; Luca Gianni
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

10.  Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines.

Authors:  P M Duffy; M C Hayes; A Cooper; C J Smart
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more
  12 in total

1.  Interaction of Anthracycline 3'-azido-epirubicin with Calf Thymus DNA via Spectral and Molecular Modeling Techniques.

Authors:  Fengling Cui; Xiaoqing Niu; Luyao Li; Pengge Zhang; Guisheng Zhang
Journal:  J Fluoresc       Date:  2015-06-25       Impact factor: 2.217

2.  Approved Anti-cancer Drugs Target Oncogenic Non-coding RNAs.

Authors:  Sai Pradeep Velagapudi; Matthew G Costales; Balayeshwanth R Vummidi; Yoshio Nakai; Alicia J Angelbello; Tuan Tran; Hafeez S Haniff; Yasumasa Matsumoto; Zi Fu Wang; Arnab K Chatterjee; Jessica L Childs-Disney; Matthew D Disney
Journal:  Cell Chem Biol       Date:  2018-06-28       Impact factor: 8.116

3.  Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes Bearing Functionally Diverse 2-Phenylpyridine Ligands.

Authors:  Adam J Millett; Abraha Habtemariam; Isolda Romero-Canelón; Guy J Clarkson; Peter J Sadler
Journal:  Organometallics       Date:  2015-03-25       Impact factor: 3.876

4.  Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway.

Authors:  Ying Pang; Chunzhang Yang; Jan Schovanek; Herui Wang; Petra Bullova; Veronika Caisova; Garima Gupta; Katherine I Wolf; Gregg L Semenza; Zhengping Zhuang; Karel Pacak
Journal:  Oncotarget       Date:  2017-04-04

5.  Modeling the Distribution of Diprotic Basic Drugs in Liposomal Systems: Perspectives on Malaria Nanotherapy.

Authors:  Ernest Moles; Maria Kavallaris; Xavier Fernàndez-Busquets
Journal:  Front Pharmacol       Date:  2019-09-25       Impact factor: 5.810

6.  Idarubicin-Gold Complex: From Crystal Growth to Gold Nanoparticles.

Authors:  Carole Barbey; Nadia Bouchemal; Pascal Retailleau; Nathalie Dupont; Jolanda Spadavecchia
Journal:  ACS Omega       Date:  2021-01-04

7.  Hydrophilic Polyhedral Oligomeric Silsesquioxane, POSS(OH)32, as a Complexing Nanocarrier for Doxorubicin and Daunorubicin.

Authors:  Kinga Piorecka; Anna Janaszewska; Marta Majkowska; Monika Marcinkowska; Jan Kurjata; Slawomir Kazmierski; Ewa Radzikowska-Cieciura; Bartlomiej Kost; Przemyslaw Sowinski; Barbara Klajnert-Maculewicz; Wlodzimierz A Stanczyk
Journal:  Materials (Basel)       Date:  2020-12-03       Impact factor: 3.623

8.  Subcellular localization of anthracyclines in cultured rat cardiomyoblasts as possible predictors of cardiotoxicity.

Authors:  Kazimierz Studzian; Krzysztof Kik; Malgorzata Lukawska; Irena Oszczapowicz; Malgorzata Strek; Leszek Szmigiero
Journal:  Invest New Drugs       Date:  2015-08-14       Impact factor: 3.850

9.  Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity.

Authors:  Hajime Kashima; Fumiyasu Momose; Hiroshi Umehara; Nao Miyoshi; Naohisa Ogo; Daisuke Muraoka; Hiroshi Shiku; Naozumi Harada; Akira Asai
Journal:  PLoS One       Date:  2016-06-10       Impact factor: 3.240

Review 10.  Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity.

Authors:  Marwa Tantawy; Frances G Pamittan; Sonal Singh; Yan Gong
Journal:  Clin Transl Sci       Date:  2020-08-28       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.